Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Promoting excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
In spite of spectacular advances in the treatment of acute coronary syndromes in the past few years, they are still characterized by a high mortality which in real life is more than 10% at 6 months. This joint Symposium between the ESC and AHA provided an update on the most recent studies on the mechanisms responsible for acute coronary syndromes and on new potential targets for the anti-thrombotic and anti-inflammatory treatments.
Pullback during angio to generate Chemogram
Inflammation regulates the fragility of the fibrous cap, as well as the thrombogenic potential of the plaque.
Main features of inflammation associated with ACS:
Nonspecific anti-inflammatory drugs
Specific antagonists of key cytokines
Della Bona R. Curr Pharm Des 2011;17:4172-89
As noted in the diagram, some patients may benefit from a larger relative contribution of antiplatelet therapy while others may need more anticoagulant therapy. The relative needs in individual patients may also change as time progresses after their ACS event.
From bench to practice: pathogenesis and treatment of acute coronary syndromes